ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02628574
Recruitment Status : Recruiting
First Posted : December 11, 2015
Last Update Posted : January 17, 2018
Sponsor:
Information provided by (Responsible Party):
Leap Therapeutics, Inc.

December 1, 2015
December 11, 2015
January 17, 2018
January 2016
March 2020   (Final data collection date for primary outcome measure)
Adverse events [ Time Frame: through 30 days post last dose ]
Any adverse change in health or side effect from the initiation of the study drug dose TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab through completion or premature withdrawal
Adverse events [ Time Frame: through 30 days post last dose ]
Any adverse change in health or side effect from the initiation of the study drug dose through completion or premature withdrawal
Complete list of historical versions of study NCT02628574 on ClinicalTrials.gov Archive Site
  • TRX518 peak concentration (Cmax) [ Time Frame: various timepoints through 1 week post dose ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
  • Time to peak concentration (Tmax) [ Time Frame: various timepoints through 1 week post dose ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
  • Area under the curve (AUC) [ Time Frame: various timepoints through 1 week post dose ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
  • RECIST assessment for evidence of antitumor activity [ Time Frame: up to 1 year ]
    RECIST assessment to determine effects of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab on solid tumors.
  • TRX518 peak concentration (Cmax) [ Time Frame: various timepoints through 1 week post dose ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
  • Time to peak concentration (Tmax) [ Time Frame: various timepoints through 1 week post dose ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
  • Area under the curve (AUC) [ Time Frame: various timepoints through 1 week post dose ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
  • RECIST assessment for evidence of antitumor activity [ Time Frame: up to 1 year ]
    RECIST assessment to determine effects of TRX518 on solid tumors.
Not Provided
Not Provided
 
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors

This study will be conducted in 5 parts (Parts A, B, C, D and E).

Monotherapy Treatment:

Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A. Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part B).

Combination Treatment:

Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Subjects will receive TRX518 in combination with gemcitabine (Part C), pembrolizumab (Part D), or nivolumab (Part E). Dose escalation will be performed for each part (Part Cesc, Part Desc, Part Eesc) and Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part Cexp, Part Dexp, Part Eexp).

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Solid Tumors
  • Drug: TRX518 monotherapy
    comparison of different (ascending) doses of TRX518 monotherapy
  • Drug: TRX518 with gemcitabine
    comparison of different (ascending) doses of TRX518 in combination with gemcitabine
  • Drug: TRX518 with pembrolizumab
    comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
  • Drug: TRX518 with nivolumab
    comparison of different (ascending) doses of TRX518 in combination with nivolumab
  • Experimental: TRX518 monotherapy (Parts A and B)
    Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
    Intervention: Drug: TRX518 monotherapy
  • Experimental: TRX518 with gemcitabine (Part C)
    Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
    Intervention: Drug: TRX518 with gemcitabine
  • Experimental: TRX518 with pembrolizumab (Part D
    Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
    Intervention: Drug: TRX518 with pembrolizumab
  • Experimental: TRX518 with nivolumab (Part E)
    Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
    Intervention: Drug: TRX518 with nivolumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
146
44
September 2020
March 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Advanced Solid Malignancies: Histologically documented metastatic or locally advanced, incurable solid malignancy (Parts A and B); histologically documented metastatic or locally advanced, incurable solid malignancy for which gemcitabine is clinically appropriate (e.g., non-small cell lung, breast, ovarian, pancreatic, and renal cancer); histologically documented metastatic or locally advanced, incurable solid malignancy for which pembrolizumab (Part D) or nivolumab (Part E) is approved. NOTE: Parts D and E only: Subject has either (1) received treatment with pembrolizumab or nivolumab for ≥4 months with a best response of stable disease and plans to continue treatment with either pembrolizumab or nivolumab in accordance with package insert; or (2) is not currently taking, but is eligible for treatment with, pembrolizumab or nivolumab in accordance with the approved indications for each as referenced in the package insert.
  • Expected survival of at least 12 weeks after dosing.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Evidence of adequate organ function by standard laboratory tests.
  • All female subjects of child bearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least 8 weeks after the last dose of study drug.

Exclusion Criteria:

  • Hematologic malignancies or multiple myeloma.
  • Known, clinically important cardiac or respiratory disease
  • Any concomitant serious physical illness other than cancer (e.g., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. No history of autoimmune disease.
  • Active, uncontrolled infections within 7 days of study entry requiring systemic therapy.
  • Evidence of progression of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing.
  • History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment. (Parts C, D and E only).
  • Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis (Parts D and E only).
  • Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment (Parts D and E only).
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis (Parts D and E only).
  • History of interstitial lung disease (Parts D and E only).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Cyndi Sirard, MD (617) 714-0357 CSirard@leaptx.com
Contact: Reena Lynam (617) 665-5206 RLynam@leaptx.com
United States
 
 
NCT02628574
TRX518-003
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
Not Provided
Study Chair: Cyndi Sirard, MD Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP